JP5366358B2 - Agent for acting on skin aging mechanism, anti-aging skin external preparation, and anti-aging method - Google Patents
Agent for acting on skin aging mechanism, anti-aging skin external preparation, and anti-aging method Download PDFInfo
- Publication number
- JP5366358B2 JP5366358B2 JP2006268345A JP2006268345A JP5366358B2 JP 5366358 B2 JP5366358 B2 JP 5366358B2 JP 2006268345 A JP2006268345 A JP 2006268345A JP 2006268345 A JP2006268345 A JP 2006268345A JP 5366358 B2 JP5366358 B2 JP 5366358B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- extract
- aging
- human
- ethyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003712 anti-aging effect Effects 0.000 title claims description 23
- 238000002360 preparation method Methods 0.000 title claims description 23
- 230000009759 skin aging Effects 0.000 title description 15
- 238000000034 method Methods 0.000 title description 9
- 230000007246 mechanism Effects 0.000 title description 4
- 239000000284 extract Substances 0.000 claims description 77
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 71
- 235000019441 ethanol Nutrition 0.000 claims description 39
- 230000037319 collagen production Effects 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 102000004266 Collagen Type IV Human genes 0.000 claims description 17
- 108010042086 Collagen Type IV Proteins 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 16
- 210000002950 fibroblast Anatomy 0.000 claims description 16
- 241000555745 Sciuridae Species 0.000 claims description 15
- 102000012422 Collagen Type I Human genes 0.000 claims description 13
- 108010022452 Collagen Type I Proteins 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 11
- 239000012190 activator Substances 0.000 claims description 7
- 239000000419 plant extract Substances 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 58
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 230000000694 effects Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 241000270322 Lepidosauria Species 0.000 description 20
- 239000006071 cream Substances 0.000 description 19
- 239000004615 ingredient Substances 0.000 description 19
- 229940058015 1,3-butylene glycol Drugs 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 235000019437 butane-1,3-diol Nutrition 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- -1 packs Substances 0.000 description 17
- 239000008213 purified water Substances 0.000 description 17
- 230000001076 estrogenic effect Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 238000010438 heat treatment Methods 0.000 description 14
- 239000006210 lotion Substances 0.000 description 14
- 239000002537 cosmetic Substances 0.000 description 12
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 230000002335 preservative effect Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 8
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 8
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 7
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 7
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 210000002469 basement membrane Anatomy 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000002304 perfume Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 6
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000008117 stearic acid Substances 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 229940075507 glyceryl monostearate Drugs 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940054269 sodium pyruvate Drugs 0.000 description 4
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 3
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 229940074979 cetyl palmitate Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940119170 jojoba wax Drugs 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- WEAKOQKTQAUHGL-WCEVMLKJSA-N (2r)-2-[[(2s)-5-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[2-[[(2s)-5-amino-2-[[(2s)-1-(2,4-dinitrophenyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethyl Chemical compound NC(=N)NCCC[C@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O WEAKOQKTQAUHGL-WCEVMLKJSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000721153 Chloranthus japonicus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 206010067572 Oestrogenic effect Diseases 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 229940069445 licorice extract Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 2
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GLXBPZNFNSLJBS-UHFFFAOYSA-N 11-methyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCC(C)C GLXBPZNFNSLJBS-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- SUZRRICLUFMAQD-UHFFFAOYSA-N N-Methyltaurine Chemical compound CNCCS(O)(=O)=O SUZRRICLUFMAQD-UHFFFAOYSA-N 0.000 description 1
- 241000596467 Ononis Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000580955 Sapindus mukorossi Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241001621335 Synodontidae Species 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- RXSUFCOOZSGWSW-UHFFFAOYSA-M acetyloxy-(4-aminophenyl)mercury Chemical compound CC(=O)O[Hg]C1=CC=C(N)C=C1 RXSUFCOOZSGWSW-UHFFFAOYSA-M 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 108010006161 conchiolin Proteins 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229940072117 fennel extract Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000020737 peppermint extract Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000009538 yokuinin Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
本発明は、化粧料等の皮膚外用剤の有効成分として有用な、老化機構に作用する種々の剤に関する。また、本発明は抗老化用皮膚外用剤及び皮膚の抗老化方法に関する。 The present invention relates to various agents that act on the aging mechanism and are useful as active ingredients for external preparations for skin such as cosmetics. The present invention also relates to an anti-aging skin external preparation and a skin anti-aging method.
従来、乳液、クリーム、化粧水、パック、洗浄料、分散液、軟膏、液剤、エアゾール、貼付剤、パップ剤、リニメント剤等の皮膚外用剤には、これらに所定の薬効を付与することを目的として種々の薬効成分が加えられている。近年、皮膚のトラブルの原因が種々解明され、それに伴い、皮膚外用剤、特に化粧料に対する消費者のニーズも細分化されつつある。例えば、老化により、表皮と真皮との間に存在する基底膜が構造変化することや機能低下することが知られている。また、真皮を形成している細胞外マトリックスが、紫外線の照射等により活性化されたマトリックスメタロプロテアーゼ（ＭＭＰ）によって分解されること等も知られている。従って、基底膜を構成するコラーゲンの産生を促進させるエストロゲン様の作用を発揮することにより、細胞外マトリックスを分解するＭＭＰの活性化を阻害することにより、細胞外マトリックスを構成する蛋白質を分泌する繊維芽細胞を賦活化することにより、又は細胞外マトリックスや基底膜を構成するコラーゲンの産生を促進することにより、抗老化作用を示す剤の提供が望まれている。 Conventionally, for the purpose of imparting prescribed medicinal effects to skin external preparations such as emulsions, creams, lotions, packs, cleaning agents, dispersions, ointments, solutions, aerosols, patches, poultices, liniments, etc. Various medicinal ingredients are added. In recent years, various causes of skin troubles have been elucidated, and along with this, consumer needs for external preparations for skin, particularly cosmetics, are being subdivided. For example, it is known that the basement membrane existing between the epidermis and the dermis undergoes a structural change or functional deterioration due to aging. It is also known that the extracellular matrix forming the dermis is degraded by matrix metalloprotease (MMP) activated by irradiation with ultraviolet rays or the like. Therefore, a fiber that secretes the protein that constitutes the extracellular matrix by inhibiting the activation of MMP that degrades the extracellular matrix by exerting an estrogen-like action that promotes the production of collagen constituting the basement membrane It is desired to provide an agent exhibiting an anti-aging effect by activating blast cells or promoting the production of collagen constituting the extracellular matrix or basement membrane.
一方、皮膚外用剤に配合される有効成分としては、皮膚に対する安全性も重要であることから、従来、天然物由来の剤である種々の植物抽出物が皮膚外用剤の有効成分として提案されている。例えば、ヒトリシズカ抽出物からなる保湿剤が提案されている（特許文献１）。
本発明は、皮膚に対する安全性が高く、皮膚外用剤の有効成分等として有用な、新規な、繊維芽細胞賦活剤、ＭＭＰ活性阻害剤、Ｉ型コラーゲン産生促進剤、IV型コラーゲン産生促進剤、及びエストロゲン様作用発現剤を提供することを課題とする。
また、本発明は、抗老化効果に優れた、抗老化用皮膚外用剤を提供することを課題とする。
また、本発明は、新規な皮膚の抗老化方法を提供することを課題とする。
The present invention is a novel fibroblast activator, MMP activity inhibitor, type I collagen production promoter, type IV collagen production promoter, which is highly safe for the skin and useful as an active ingredient of an external preparation for skin, It is another object of the present invention to provide an estrogen-like action expression agent.
Moreover, this invention makes it a subject to provide the skin external preparation for anti-aging which was excellent in the anti-aging effect.
Another object of the present invention is to provide a novel skin anti-aging method.
前記課題を解決するため、本発明は、ヒトリシズカ抽出物を有効成分とする繊維芽細胞賦活剤；ヒトリシズカ抽出物を有効成分とするマトリックスメタロプロテアーゼ（ＭＭＰ）活性阻害剤；ヒトリシズカ抽出物を有効成分とするＩ型コラーゲン産生促進剤；ヒトリシズカ抽出物を有効成分とするIV型コラーゲン産生促進剤；及びヒトリシズカ抽出物を有効成分とするエストロゲン様作用発現剤；を提供する。
また、別の観点から、本発明によって、ヒトリシズカ抽出物を有効成分として含有する抗老化用皮膚外用剤；及びヒトリシズカ抽出物を供給することによって、繊維芽細胞を賦活化、ＭＭＰ活性を阻害、Ｉ型コラーゲン産生を促進、IV型コラーゲン産生を促進、又はエストロゲン様作用を発現して、皮膚の老化を防止する方法；が提供される。
In order to solve the above-mentioned problems, the present invention provides a fibroblast activator comprising a human lizard extract as an active ingredient; a matrix metalloprotease (MMP) activity inhibitor comprising a human lizard extract as an active ingredient; A type I collagen production promoter; a type IV collagen production promoter containing human lysizuka extract as an active ingredient; and an estrogen-like action expression agent containing human lysizuka extract as an active ingredient.
From another point of view, according to the present invention, an anti-aging external preparation for skin containing human lysizuka extract as an active ingredient; and supplying human sizizuka extract to activate fibroblasts and inhibit MMP activity, A method for preventing skin aging by promoting type I collagen production, type IV collagen production, or expressing an estrogenic effect.
本発明によれば、老化機構に関与して、抗老化作用を奏する、新規な剤及び新規な方法を提供することができる。また、本発明によれば、抗老化効果に優れた、抗老化用皮膚外用剤を提供することができる。 ADVANTAGE OF THE INVENTION According to this invention, it can participate in an aging mechanism and can provide the novel agent and novel method which show | play an anti-aging effect. Moreover, according to this invention, the anti-aging skin external preparation excellent in the anti-aging effect can be provided.
以下、本発明について詳細に説明する。なお、本明細書において、「〜」はその前後の数値を含む範囲を意味するものとする。
本発明の老化機構に関与する種々の剤、即ち、繊維芽細胞賦活剤、ＭＭＰ活性阻害剤、Ｉ型コラーゲン産生促進剤、IV型コラーゲン産生促進剤及びエストロゲン様作用発現剤（以下、総称して「抗老化剤」という）は、センリョウ科チャラン属ヒトリシズカ（学名：Chloranthus japonicus）抽出物を有効成分とする。本発明に用いられるヒトリシズカ抽出物は、抽出部位についての制限はなく、ヒトリシズカの根、茎、葉、花序、果実、種子等いずれの部分の抽出物であってもよい。又、本発明の抗老化剤には、ヒトリシズカの２箇所以上から得られた抽出物を混合してもよく、あるいは２箇所以上の部分から異なる溶媒により抽出された抽出物を二種以上混合して用いてもよい。
Hereinafter, the present invention will be described in detail. In the present specification, “to” means a range including numerical values before and after.
Various agents involved in the aging mechanism of the present invention, that is, fibroblast activator, MMP activity inhibitor, type I collagen production promoter, type IV collagen production promoter and estrogen-like action expression agent (hereinafter collectively referred to as “genetic agent”). “Anti-aging agent”) contains an extract of the genus Chloranthus japonicus (scientific name: Chloranthus japonicus) as an active ingredient. There is no restriction | limiting about an extraction site | part, and the extract of any parts, such as a root, stem, a leaf, an inflorescence, a fruit, and a seed of a human lizardfish, may be sufficient as the human lizard extract used for this invention. In addition, the anti-aging agent of the present invention may be mixed with extracts obtained from two or more places of human lizard, or two or more extracts extracted from two or more portions with different solvents. May be used.
前記ヒトリシズカ抽出物は、ヒトリシズカの根、茎、葉、花序、果実、種子等の１箇所又は２箇所以上を、適当な溶媒によって抽出し、溶媒を留去することにより得られる。これらの部分に乾燥、細切、圧搾、又は発酵などの適宜の処理を施した後、抽出処理等を施してもよい。抽出は、ヒトリシズカを低温ないし加温下で溶媒中に所定の時間浸漬することによって実施できる。抽出溶媒は特に限定されないが、水、又はメチルアルコール、エチルアルコール等の低級１価アルコール；グリセリン、プロピレングリコール、１，３−ブチレングリコール等の液状多価アルコール；アセトン等のケトン類；エチルエーテル等のエーテル類；もしくは酢酸エチル等のエステル類；等の有機溶媒の一種又は二種以上を、及びこれらと水との混合溶媒を用いることができる。 The human squirrel extract is obtained by extracting one or two or more parts such as roots, stems, leaves, inflorescences, fruits, and seeds of the squirrel with a suitable solvent, and distilling off the solvent. These portions may be subjected to an appropriate treatment such as drying, chopping, pressing, or fermentation, followed by an extraction treatment or the like. Extraction can be carried out by immersing human lizard in a solvent at a low temperature or under heating for a predetermined time. The extraction solvent is not particularly limited, but water or lower monohydric alcohols such as methyl alcohol and ethyl alcohol; liquid polyhydric alcohols such as glycerin, propylene glycol and 1,3-butylene glycol; ketones such as acetone; ethyl ether and the like 1 type or 2 types or more of organic solvents, such as these ethers; or esters, such as ethyl acetate; and the mixed solvent of these and water can be used.
前記ヒトリシズカ抽出物は、そのまま皮膚外用剤に配合してもよいし、適宜の期間そのまま放置し、熟成させた後に用いることもできる。必要ならば、効果に影響のない範囲で、さらにろ過やイオン交換樹脂等による脱臭、脱色等の精製処理を施した後に用いることもできる。又、液体クロマトグラフィー等の分離手段を用いて、活性の高い画分のみを用いることもできる。 The human squirrel extract may be used as it is in a skin external preparation, or may be used after being left to stand for an appropriate period and aged. If necessary, it can be used after further purification treatment such as filtration, deodorization and decolorization with an ion exchange resin or the like within a range not affecting the effect. Further, only a fraction having a high activity can be used by using a separation means such as liquid chromatography.
前記ヒトリシズカ抽出物の好ましい調製方法の例としては、ヒトリシズカを、含水もしくは非含水のエチルアルコール等のアルコール系溶媒、含水もしくは非含水の１，３−ブチレングリコール等の多価アルコール系溶媒、又は水を用い、室温又は加温して１〜５日間抽出を行った後、ろ過し、得られたろ液を、さらに１週間程度放置して熟成させ、再び、ろ液をろ過する方法が挙げられる。 Examples of preferred methods for preparing the human lizard extract include human lizards, alcoholic solvents such as hydrous or non-hydrated ethyl alcohol, polyhydric alcohol solvents such as hydrous or non-hydrated 1,3-butylene glycol, or water. The mixture is filtered at room temperature or warmed for 1 to 5 days, filtered, and the filtrate obtained is left to mature for about one week, and the filtrate is filtered again.
抽出物中の成分としては、フラボノイド配糖体、フェノール類、アミノ酸、トリテルペン等が挙げられる。抽出溶媒中のアルコール系溶媒又は多価アルコール系溶媒の含有量が高いほど、トリテルペンの含有量が高くなる。
本発明の繊維芽細胞賦活剤、ＭＭＰ活性阻害剤、Ｉ型コラーゲン産生促進剤、又はIV型コラーゲン産生促進剤に用いるヒトリシズカ抽出物は、その抽出溶媒が、水と１価アルコールとの混合溶媒であるのが好ましく、水とエチルアルコールとの混合溶媒であるのがより好ましく、エチルアルコールの混合割合が５０体積％（以下「ｖｏｌ％」という）以上である水とエチルアルコールとの混合溶媒であるのがさらに好ましい。
一方、本発明のエストロゲン様作用発現剤に用いるヒトリシズカ抽出物は、その抽出溶媒が、水のみ、又は水と１価アルコールとの混合溶媒であるのが好ましく、水のみであるのがより好ましい。
Examples of the components in the extract include flavonoid glycosides, phenols, amino acids, triterpenes and the like. The higher the content of the alcohol solvent or polyhydric alcohol solvent in the extraction solvent, the higher the triterpene content.
The human sizzle extract used in the fibroblast activator, MMP activity inhibitor, type I collagen production promoter, or type IV collagen production promoter of the present invention is a mixed solvent of water and monohydric alcohol. Preferably, it is a mixed solvent of water and ethyl alcohol, more preferably a mixed solvent of water and ethyl alcohol in which the mixing ratio of ethyl alcohol is 50% by volume (hereinafter referred to as “vol%”) or more. Is more preferable.
On the other hand, as for the human squirrel extract used for the estrogen-like action-expressing agent of the present invention, the extraction solvent is preferably water alone or a mixed solvent of water and a monohydric alcohol, more preferably water alone.
前記ヒトリシズカ抽出物は、抽出液として、スプレードライ等により乾燥させて粉末状として、又は使用目的に合わせて乾燥固形分もしくは粉末を適切な溶媒と混合して用いることができる。即ち、液状、ペースト状、ゲル状等のいずれの形態で、本発明の抗老化剤の有効成分として用いてもよい。 The human lizard extract can be used as an extract, dried by spray drying or the like, or in a powder form, or a dry solid or powder mixed with an appropriate solvent according to the intended use. That is, it may be used as an active ingredient of the anti-aging agent of the present invention in any form such as liquid, paste or gel.
ここで、繊維芽細胞の賦活化、ＭＭＰ活性の阻害、Ｉ型又はIV型コラーゲン産生の促進、及びエストロゲン様作用の発現と、抗老化効果との関連性について説明する。
皮膚は主に表皮及び真皮から構成されており、その２層間に基底膜という膜様構造体が存在する。真皮を形成している細胞外マトリックスは、主にＩ型コラーゲン、III型コラーゲン、エラスチン等であり、これらのタンパク質の構成成分は線維芽細胞から分泌される。細胞外マトリックスはＭＭＰにより分解を受ける。ＭＭＰの分泌や活性上昇は、紫外線等により上昇することが知られている。また、IV型コラーゲンは基底膜の一構成成分であることが知られる。基底膜の老化による構造変化や機能低下が知られており、エストロゲンは女性ホルモンの一種であり、コラーゲン産生を促進させることが知られている。
すなわち、真皮を構成するタンパク質を分泌する線維芽細胞を賦活化させること、細胞外マトリックスの分解に関与するＭＭＰ（例えば、ＭＭＰ−２）の活性を阻害すること、真皮や基底膜の構成成分であるＩ型コラーゲン又はIV型コラーゲンの産生を促進すること、及びコラーゲンの産生を促進するエストロゲン様作用を発現することにより、皮膚の老化防止効果が期待できる。
Here, the relationship between the activation of fibroblasts, the inhibition of MMP activity, the promotion of type I or type IV collagen production, and the expression of an estrogen-like action and the anti-aging effect will be described.
The skin is mainly composed of epidermis and dermis, and a membrane-like structure called basement membrane exists between the two layers. The extracellular matrix forming the dermis is mainly type I collagen, type III collagen, elastin and the like, and the constituent components of these proteins are secreted from fibroblasts. The extracellular matrix is degraded by MMP. It is known that MMP secretion and increased activity are increased by ultraviolet rays and the like. In addition, type IV collagen is known to be a component of the basement membrane. Structural changes and functional decline due to aging of the basement membrane are known, and estrogen is a kind of female hormone and is known to promote collagen production.
That is, it activates fibroblasts that secrete proteins that constitute the dermis, inhibits the activity of MMPs (eg, MMP-2) involved in the degradation of the extracellular matrix, and is a constituent of the dermis and basement membrane A skin aging prevention effect can be expected by promoting the production of certain type I or type IV collagen and expressing an estrogen-like action that promotes the production of collagen.
本発明の抗老化剤は、種々の用途に用いることができる。皮膚に対する安全性が良好であるので、皮膚外用剤中に配合することが好ましい。その他、本発明の抗老化剤は、食品（飲料を含む）に配合することもできる。前記食品としては、特に制限されないが、具体的には、例えば、飴、チューインガム、飲料等が挙げられる。 The anti-aging agent of this invention can be used for various uses. Since the safety to the skin is good, it is preferably blended into the external preparation for skin. In addition, the anti-aging agent of this invention can also be mix | blended with foodstuffs (a drink is included). Although it does not restrict | limit especially as said foodstuff, Specifically, a salmon, chewing gum, a drink etc. are mentioned, for example.
次に、本発明の皮膚外用剤について詳細に説明する。
本発明の皮膚外用剤は、本発明の抗老化剤であるヒトリシズカ抽出物を有効成分として含有する抗老化用皮膚外用剤である。前記抗老化剤の配合量については特に制限はないが、最終形態である皮膚外用剤の全質量に対して、前記ヒトリシズカ抽出物が固形分として０．００００５〜１．５質量％（以下、単に「％」という）であるのが好ましく、０．０００５〜１．５％であるのがより好ましい。この範囲内であれば、該成分を安定的に配合することができ、且つ高い繊維芽細胞の賦活化、ＭＭＰ活性の阻害、Ｉ型コラーゲン産生の促進、IV型コラーゲン産生の促進、又はエストロゲン様作用の発現をもたらし、それに基づく高い抗老化作用を発揮することができる。また、抽出液を使用する場合は、溶質であるヒトリシズカ抽出物の含有量が上記範囲内であれば、その抽出液濃度は何ら限定されるものではない。
Next, the skin external preparation of the present invention will be described in detail.
The skin external preparation of the present invention is an anti-aging skin external preparation containing, as an active ingredient, the human lizard extract that is the anti-aging agent of the present invention. Although there is no restriction | limiting in particular about the compounding quantity of the said anti-aging agent, The said human lizard extract is 0.00005-1.5 mass% (henceforth, only below) as solid content with respect to the total mass of the skin external preparation which is a final form. "%") Is preferable, and 0.0005 to 1.5% is more preferable. Within this range, the component can be stably blended, and high fibroblast activation, inhibition of MMP activity, promotion of type I collagen production, promotion of type IV collagen production, or estrogen-like It brings about the expression of the action and can exert a high anti-aging action based on it. In addition, when the extract is used, the concentration of the extract is not limited as long as the content of the human squirrel extract as a solute is within the above range.
本発明の皮膚外用剤の形態は、特に限定されず、例えば、乳液、クリーム、化粧水、美容液、パック、洗浄料、メーキャップ化粧料、分散液、軟膏、液剤、エアゾール、貼付剤、パップ剤、リニメント剤等の、いずれの形態の化粧料であっても外用医薬品等であってもよい。 The form of the external preparation for skin of the present invention is not particularly limited, and examples thereof include emulsions, creams, lotions, cosmetics, packs, cleaning agents, makeup cosmetics, dispersions, ointments, solutions, aerosols, patches, and cataplasms. Any form of cosmetic, such as a liniment, may be an external medicine.
又、本発明の皮膚外用剤は、前記ラジカル消去剤以外に、化粧料や医薬部外品、外用医薬品等に通常使用される各種の成分、即ち、水、アルコール、油剤、界面活性剤、増粘剤、粉体、キレート剤、ｐＨ調整剤、紫外線吸収剤、動植物・微生物由来の抽出物、保湿剤・美白剤・抗炎症剤・細胞賦活剤等の各種薬効剤、香料等を、本発明の効果を損なわない範囲で適宜加えることができる。 In addition to the radical scavenger, the skin external preparation of the present invention includes various components that are usually used in cosmetics, quasi-drugs, external medicines, ie, water, alcohols, oils, surfactants, Viscosity, powder, chelating agent, pH adjuster, UV absorber, extracts from animals and plants / microorganisms, various medicinal agents such as moisturizers, whitening agents, anti-inflammatory agents, cell activators, fragrances, etc. As long as the effect is not impaired, it can be added as appropriate.
本発明は、ヒトリシズカ抽出物を供給することによって、皮膚の老化を防止する方法にも関する。例えば、皮膚の表面に適用して、繊維芽細胞を賦活化、ＭＭＰ活性を阻害、Ｉ型コラーゲン産生を促進、IV型コラーゲン産生を促進、又はエストロゲン様作用を発現して、皮膚の老化を防止し、皮膚の状態の改善、より具体的には、皮膚のしわやたるみを防止又は改善するために利用してもよい。皮膚のしわやたるみを防止又は改善して、皮膚の外観の改善、即ち、美容を目的とするのに利用することができる。 The present invention also relates to a method of preventing skin aging by providing a human lizard extract. For example, it can be applied to the skin surface to activate fibroblasts, inhibit MMP activity, promote type I collagen production, promote type IV collagen production, or develop estrogenic action to prevent skin aging It may be used to improve skin condition, more specifically, to prevent or improve skin wrinkles and sagging. It can be used to prevent or improve skin wrinkles and sagging and to improve the appearance of the skin, that is, for cosmetic purposes.
以下、本発明を実施例によりさらに具体的に説明するが、本発明の範囲は下記の実施例に限定されることはない。
［例１：ヒトリシズカ８０ｖｏｌ％含水エチルアルコール抽出物の製造例］
ヒトリシズカの全草１０ｇに、８０ｖｏｌ％含水エチルアルコール（エチルアルコールの割合が８０ｖｏｌ％）を１５０ｍＬ加え、室温又は加温して１日抽出を行った後、ろ過し、得られたろ液中の溶媒を留去して乾固し、固形分であるヒトリシズカの８０ｖｏｌ％含水エチルアルコール抽出物（収量０．８ｇ）を得た。
Hereinafter, the present invention will be described more specifically with reference to examples. However, the scope of the present invention is not limited to the following examples.
[Example 1: Manufacture of 80 vol% hydrous ethyl alcohol extract of human lizards]
150 g of 80 vol% hydrated ethyl alcohol (the ratio of ethyl alcohol is 80 vol%) is added to 10 g of the whole plant of human squirrel and extracted at room temperature or heated for one day, followed by filtration, and the solvent in the obtained filtrate is filtered. Distilled to dryness, an 80 vol% water-containing ethyl alcohol extract (yield 0.8 g) of human lizards as a solid content was obtained.
［例２：ヒトリシズカ５０ｖｏｌ％含水エチルアルコール抽出物の製造例］
ヒトリシズカの全草１０ｇに、５０ｖｏｌ％含水エチルアルコール（エチルアルコールの割合が５０ｖｏｌ％）１５０ｍＬを加え、室温又は加温して１日抽出を行った後、ろ過し、得られたろ液中の溶媒を留去して乾固し、固形分であるヒトリシズカの５０ｖｏｌ％含水エチルアルコール抽出物（収量０．７５ｇ）を得た。
[Example 2: Example of production of human lizardka 50 vol% hydrous ethyl alcohol extract]
150 g of 50 vol% hydrated ethyl alcohol (the ratio of ethyl alcohol is 50 vol%) is added to 10 g of human squirrel whole plant, extracted at room temperature or heated for one day, filtered, and the solvent in the obtained filtrate is filtered. Distilled to dryness to obtain a 50 vol% water-containing ethyl alcohol extract (yield: 0.75 g) of human lizards as a solid content.
［例３：ヒトリシズカ精製水抽出物の製造例］
ヒトリシズカの全草１０ｇに、精製水を１５０ｍＬ加え、室温又は加温して１日抽出を行った後、ろ過し、得られたろ液中の溶媒を留去して乾固し、固形分であるヒトリシズカ精製水抽出物（収量０．７３ｇ）を得た。
[Example 3: Production example of purified water extract of Hitorizuka]
150 mL of purified water is added to 10 g of the whole plant of human lizard, and after extraction for one day at room temperature or warming, the mixture is filtered, and the solvent in the obtained filtrate is evaporated to dryness to obtain a solid content. A purified human water extract (yield 0.73 g) was obtained.
［例４：線維芽細胞賦活作用の評価］
（測定方法）
２４ｗｅｌｌプレートに培地を適量加え、ヒト新生児由来皮膚線維芽細胞（ＮＢ１ＲＧＢ）を播種し、３７℃、二酸化炭素濃度５％中にて静置した。翌日、例１で得られたヒトリシズカ抽出物の最終濃度が０（対照）、１、１０、１００μｇ／ｍＬになるように試料をそれぞれ精製水に溶解させ、被験試料溶液を調製した。培養４日目に培地を交換し、再度、試料を添加した。翌日、ＭＴＴ（ＳＩＧＭＡ社製）を５ｍｇ／ｍＬになるよう調製した溶液を、各ｗｅｌｌにそれぞれ１００μＬずつ添加した。４時間培養した後、培地を除去し、イソプロパノールを用いて生成したホルマザンを溶解した。マイクロプレートリーダーを用いてリファレンスを６３０ｎｍと５７０ｎｍとで吸光度を測定し、両者の差をもってブルーホルマザン生成量とした。なお、ブルーホルマザンの生成量が多いほど、繊維芽細胞が賦活化されていることを示す。
下記表に、対照に対する比率を算出した。
[Example 4: Evaluation of fibroblast activation]
(Measuring method)
An appropriate amount of medium was added to a 24-well plate, seeded with human neonatal skin fibroblasts (NB1RGB), and allowed to stand at 37 ° C. in a carbon dioxide concentration of 5%. On the next day, the samples were dissolved in purified water so that the final concentration of the human lysizuka extract obtained in Example 1 was 0 (control), 1, 10, and 100 μg / mL to prepare a test sample solution. On the 4th day of culture, the medium was changed and the sample was added again. On the next day, 100 μL each of a solution prepared by adjusting MTT (manufactured by SIGMA) to 5 mg / mL was added to each well. After culturing for 4 hours, the medium was removed and the formazan produced using isopropanol was dissolved. Absorbance was measured at 630 nm and 570 nm using a microplate reader, and the difference between the two was used as the amount of blue formazan produced. In addition, it shows that the fibroblast is activated, so that there is much production amount of blue formazan.
In the table below, the ratio to the control was calculated.
［例５：ＭＭＰ−２活性抑制作用の評価］
（１）ＭＭＰ−２の調製
ヒトＭＭＰ−２ ｃＤＮＡを、５’ＰＣＲプライマー（５’−ｇｇｃｇｇａｔｃｃａｔｇｇｃｇｃｃｇｔｃｇｃｃｃａｔｃａｔｃ−３’）、及び３’ＰＣＲプライマー（３’−ｇｃｃｇｔｃｇａｃｔａｃａａｔｇｔｃｃｔｇｔｔｔｇｃａｇａｔ−５’）を用い、ＭＭＰ−２の３．３ｋｂ ｃＤＮＡ断片を含むｐＳＧ−ＧｅｌＡを鋳型として、ＰＣＲ反応を行った。得られた30Ａｌａから474Ｖａｌまでをコードする１．３ｋｂ ＰＣＲ断片をＢａｍ ＨＩ／Ｓａｌ Ｉで消化し、ｐＴＨ−７２発現ベクター（ｐＴＨ−ＭＭＰ２−ＰＣ）のＢａｍ ＨＩ／Ｓａｌ Ｉ部位にクローン化した。
ヒトＭＭＰ−２の発現は、Itoh, M. et al.; J.Biolchem.,119:667-673(1996)、精製及び巻き戻し（以下「リフォールディング」とする。）は、西村義文、大野茂雄 監修：タンパク実験プロトコール、細胞工学別冊 実験プロトコールシリーズ２ 構造解析編、１９９７に準じて行った。また、ｃＤＮＡは、Collier, I. E. et al.; J. Biol. Chem., 263(14), 6579-6587(1998)に記載されているものを使用した。
具体的には、ＭＭＰ−２のｃＤＮＡを含む発現ベクター（ｐＴＨ−ＭＭＰ−２）を、大腸菌ＢＬ２１（ＤＥ３）株にトランスフェクトし、ＩＰＴＧで発現誘導した。発現タンパクは、Ｎｉ−ＮＴＡ樹脂（ＱＵＩＡＧＥＮ ＩＮＣ．，米国）を用いてアフィニティー精製後、リフォールディングを行い、酢酸４−アミノフェニル水銀と３７℃、６０分間反応を行なうことで活性型へ移行させた後、ＥＤＴＡを加えた。これを酵素標本とし、蛍光性ペプチド基質（ＭＯＣＡｃ／ＤＮＰ ｐｅｐｔｉｄｅ）切断活性反応を行ない、高速液体クロマトグラフィー（カラム：Ｗａｋｏｓｉｌ５Ｃ１８、溶離液：３０％アセトニトリル＋０．１％ＴＨＦ、流速１．０ｍＬ／ｍｉｎ、検出：励起波長３２５ｎｍ、蛍光波長４１０ｎｍ）による生成物のピーク面積を測定し、これを酵素活性の指標とした。
[Example 5: Evaluation of MMP-2 activity inhibitory effect]
(1) Preparation of MMP-2 Human MMP-2 cDNA was prepared using 5 ′ PCR primer (5′-ggcggatccatggcgccgtcgcccccatc-3 ′) and 3 ′ PCR primer (3′-gccgtcgactacaatgtcctgttgtcagat-5 ′). PCR reaction was performed using pSG-GelA containing a 3.3 kb cDNA fragment as a template. The resulting 1.3 kb PCR fragment encoding 30 Ala to 474 Val was digested with Bam HI / Sal I and cloned into the Bam HI / Sal I site of the pTH-72 expression vector (pTH-MMP2-PC). .
Human MMP-2 is expressed by Itoh, M. et al .; J. Biolchem., 119: 667-673 (1996), and purified and unwound (hereinafter referred to as “refolding”) by Yoshifumi Nishimura, Ohno. Supervised by Shigeo: Performed according to Protein Experiment Protocol, Cell Engineering Separate Volume Experiment Protocol Series 2 Structural Analysis, 1997. The cDNA described in Collier, IE et al .; J. Biol. Chem., 263 (14), 6579-6587 (1998) was used.
Specifically, an expression vector (pTH-MMP-2) containing MMP-2 cDNA was transfected into E. coli BL21 (DE3) strain, and expression was induced with IPTG. The expressed protein was affinity-purified using Ni-NTA resin (QUIAGEN INC., USA), refolded, and transferred to the active form by reacting with 4-aminophenylmercuric acetate at 37 ° C. for 60 minutes. Later, EDTA was added. Using this as an enzyme sample, a fluorescent peptide substrate (MOCAc / DNP peptide) cleavage activity reaction was performed, and high performance liquid chromatography (column: Wakosil 5C18, eluent: 30% acetonitrile + 0.1% THF, flow rate 1.0 mL / min, Detection: Excitation wavelength: 325 nm, fluorescence wavelength: 410 nm) The peak area of the product was measured and used as an indicator of enzyme activity.
（２）ヒトリシズカ抽出物のＭＭＰ−２阻害活性の測定
被験試料を、蒸留水に溶解させて８．０ｍｇ／ｍＬとした後、蒸留水にて４．０ｍｇ／ｍＬ、２．０ｍｇ／ｍＬに希釈し、懸濁物を除くため、ろ過を行った。ＭＭＰ−２阻害活性の測定は、上記調製した活性型ＭＭＰ−２の４０μＬ、被験試料溶液２０μＬ、アッセイバッファー２０μＬ（トリス−塩酸緩衝液（ｐＨ７．５）５００ｍｍｏｌ／Ｌ、塩化ナトリウム１．５ｍｏｌ／Ｌ、塩化カルシウム１００ｍｍｏｌ／Ｌ、硫酸亜鉛５００μｍｏｌ／Ｌ、アジ化ナトリウム３０ｍｍｏｌ／Ｌ、Ｂｒｉｊ３５ ０．０５％）を、３７℃で１５分間プレインキュベーションした後、ＭＯＣＡｃ／ＤＮＰ ｐｅｐｔｉｄｅ １２０μＬ（４．１６μｍｏｌ／Ｌ）を添加し、３７℃で２時間反応させた後、ＥＤＴＡ １０μＬ（２００ｍｍｏｌ／Ｌ）を添加した。反応液中の生成物について高速液体クロマトグラフィー分析によるピーク面積を測定した。被験試料溶液の代わりに蒸留水を加えた反応液の生成物を１００％として、被験試料のＭＭＰ−２活性阻害率（％）を求めた。
なお、各被験試料として、ヒトリシズカ抽出物の水溶液（濃度は４００μｇ／ｍＬ）を用いた。
(2) Measurement of MMP-2 inhibitory activity of human lysizuka extract The test sample was dissolved in distilled water to 8.0 mg / mL, and then diluted with distilled water to 4.0 mg / mL and 2.0 mg / mL And filtered to remove the suspension. The MMP-2 inhibitory activity was measured by 40 μL of the prepared active MMP-2, 20 μL of test sample solution, 20 μL of assay buffer (Tris-HCl buffer (pH 7.5) 500 mmol / L, sodium chloride 1.5 mol / L). , Calcium chloride 100 mmol / L, zinc sulfate 500 μmol / L, sodium azide 30 mmol / L, Brij 35 0.05%), preincubated at 37 ° C. for 15 minutes, and then MOCAc / DNP peptide 120 μL (4.16 μmol / L) Was added and reacted at 37 ° C. for 2 hours, and then 10 μL of EDTA (200 mmol / L) was added. The peak area by the high performance liquid chromatography analysis was measured about the product in a reaction liquid. The MMP-2 activity inhibition rate (%) of the test sample was determined with the product of the reaction solution added with distilled water instead of the test sample solution as 100%.
In addition, as each test sample, the aqueous solution (concentration is 400 μg / mL) of human lizard extract.
［例６：Ｉ型コラーゲン産生促進作用の評価］
ヒト正常線維芽細胞（Ｄｅｔｒｏｉｔ ５５１）を、１０％のＦＢＳ、１％のＮＥＡＡ、及び１ｍｍｏｌ／Ｌのピルビン酸ナトリウム含有ＭＥＭを用いて培養した後、トリプシン処理により細胞を回収した。回収した細胞を２×１０5ｃｅｌｌｓ／ｍＬの濃度に上記培地で希釈した後、９６ｗｅｌｌマイクロプレートに１ｗｅｌｌ当たり１００μＬずつ播種し、一晩培養した。培養終了後、培地を抜き、０．５％のＦＢＳ含有ＭＥＭに溶解した被験試料を、各ｗｅｌｌに１５０μＬ添加し、３日間培養した。培養後、各ｗｅｌｌの培地中のコラーゲン量をＥＬＩＳＡ法により測定した。
コラーゲン産生促進作用の計算方法は以下のとおりである。
コラーゲン産生促進率（％）＝Ａ／Ｂ×１００
Ａ ：被験試料添加時のコラーゲン量
Ｂ ：被験試料無添加時のコラーゲン量
なお、各被験試料として、ヒトリシズカ抽出物の水溶液（濃度は１００μｇ／ｍＬ）を用いた。
[Example 6: Evaluation of type I collagen production promoting effect]
After normal human fibroblasts (Detroit 551) were cultured using MEM containing 10% FBS, 1% NEAA, and 1 mmol / L sodium pyruvate, the cells were collected by trypsinization. The collected cells were diluted with the above medium to a concentration of 2 × 10 5 cells / mL, then seeded at 100 μL per well on a 96-well microplate, and cultured overnight. After completion of the culture, the medium was removed, and a test sample dissolved in 0.5% FBS-containing MEM was added to each well and cultured for 3 days. After the culture, the amount of collagen in the medium of each well was measured by ELISA.
The calculation method of the collagen production promoting action is as follows.
Collagen production promotion rate (%) = A / B × 100
A: Collagen amount when test sample is added B: Collagen amount when test sample is not added Note that an aqueous solution of human lysizuka extract (concentration is 100 μg / mL) was used as each test sample.
［例７：IV型コラーゲン産生促進作用の評価］
ヒト正常線維芽細胞（ＮＢ１ＲＧＢ）を１０％のＦＢＳ含有ダルベッコＭＥＭを用いて培養した後、トリプシン処理により細胞を回収した。回収した細胞を１．６×１０5ｃｅｌｌｓ／ｍＬの濃度に上記培地で希釈した後、９６ｗｅｌｌマイクロプレートに１ｗｅｌｌ当たり１００μＬずつ播種し、一晩培養した。培養終了後、培地を抜き、０．２５％のＦＢＳ含有ダルベッコＭＥＭに溶解した被験試料を、各ｗｅｌｌに１５０μＬ添加し、３日間培養した。培養後、各ｗｅｌｌの培地中のＩＶ型コラーゲン量をＥＬＩＳＡ法により測定した。
ＩＶ型コラーゲン産生促進作用の計算方法は以下のとおりである。
ＩＶ型コラーゲン産生促進率（％）＝Ａ／Ｂ×１００
Ａ ：被験試料添加時のＩＶ型コラーゲン量
Ｂ ：被験試料無添加時のＩＶ型コラーゲン量
なお、各被験試料として、ヒトリシズカ抽出物の水溶液（濃度は下記表中に記載）を用いた。
[Example 7: Evaluation of collagen IV production promoting effect]
Human normal fibroblasts (NB1RGB) were cultured using 10% FBS-containing Dulbecco MEM, and then cells were collected by trypsin treatment. The collected cells were diluted with the above medium to a concentration of 1.6 × 10 5 cells / mL, then seeded at 100 μL per well on a 96-well microplate, and cultured overnight. After completion of the culture, the medium was removed, and 150 μL of a test sample dissolved in 0.25% FBS-containing Dulbecco MEM was added to each well and cultured for 3 days. After culture, the amount of type IV collagen in the medium of each well was measured by ELISA.
The calculation method of the type IV collagen production promoting action is as follows.
Type IV collagen production promotion rate (%) = A / B × 100
A: Type IV collagen amount when test sample is added B: Type IV collagen amount when no test sample is added Note that as each test sample, an aqueous solution of human squirrel extract (concentration is described in the table below) was used.
［例８：エストロゲン様作用の評価］
ヒト乳癌由来細胞（ＭＣＦ−７）を、１０％のＦＢＳ、１％のＮＥＡＡ及び１ｍｍｏｌ／Ｌのピルビン酸ナトリウムを含有するＭＥＭを用いて培養した後、トリプシン処理により細胞を回収した。回収した細胞を、活性炭処理した１０％のＦＢＳ、１％のＮＥＡＡ、及び１ｍｍｏｌ／Ｌのピルビン酸ナトリウムを含有するフェノールレッド不含ＭＥＭ（Ｔ−ＭＥＭ）を用いて、３．０×１０4ｃｅｌｌｓ／ｍＬの濃度に希釈した後、４８ｗｅｌｌプレートに１ｗｅｌｌあたり４５０μＬずつ播種し、細胞を定着させるため培養した。６時間後（０日目）にＴ−ＭＥＭで、最終濃度の１０倍に調製した被験試料を各ｗｅｌｌに１００μＬ添加し培養を続けた。３日目に培地を抜き、Ｔ−ＭＥＭで終濃度に調製した被験試料を各ｗｅｌｌに１ｍＬ添加し、さらに培養を続けた。エストロゲン様作用は、ＭＴＴアッセイを用いて測定した。培養終了後、培地を抜き、１％のＮＥＡＡ及び１ｍｍｏｌ／Ｌのピルビン酸ナトリウムを含有するＭＥＭに終濃度０．４ｍｇ／ｍＬで溶解したＭＴＴを、各ｗｅｌｌに２００μＬずつ添加した。２時間培養した後に、細胞内に生成したブルーホルマザンを２−プロパノール２００μＬで抽出した。抽出後、波長５７０ｎｍにおける吸光度を測定した。同時に濁度として波長６５０ｎｍにおける吸光度を測定し、両者の差をもってブルーホルマザン生成量とした。なお、ブルーホルマザンの生成量が多いほど、エストロゲン様作用が高いことを示す。ポジティブコントロールとして、１０-9ｍｏｌ／Ｌエストラジオールを使用した。
エストロゲン様作用の計算方法は以下のとおりである。
エストロゲン様作用率（％）＝Ａ／Ｂ×１００
Ａ ：被験試料添加時の吸光度
Ｂ ：被験試料無添加時の吸光度
なお、各被験試料として、ヒトリシズカ抽出物の水溶液（濃度は下記表中に記載）を用いた。
[Example 8: Evaluation of estrogenic effect]
Human breast cancer-derived cells (MCF-7) were cultured using MEM containing 10% FBS, 1% NEAA and 1 mmol / L sodium pyruvate, and then cells were collected by trypsin treatment. The recovered cells were treated with 3.0 × 10 4 cells using phenol red-free MEM (T-MEM) containing activated carbon-treated 10% FBS, 1% NEAA, and 1 mmol / L sodium pyruvate. After dilution to a concentration of / mL, 450 μL per well was seeded on a 48-well plate and cultured to fix the cells. Six hours later (day 0), 100 μL of a test sample prepared to 10 times the final concentration was added to each well with T-MEM, and the culture was continued. On the third day, the medium was removed, 1 mL of a test sample prepared to a final concentration with T-MEM was added to each well, and the culture was further continued. Estrogen-like effects were measured using the MTT assay. After completion of the culture, the medium was removed, and 200 μL of MTT dissolved in MEM containing 1% NEAA and 1 mmol / L sodium pyruvate at a final concentration of 0.4 mg / mL was added to each well. After culturing for 2 hours, blue formazan produced in the cells was extracted with 200 μL of 2-propanol. After extraction, the absorbance at a wavelength of 570 nm was measured. At the same time, the absorbance at a wavelength of 650 nm was measured as turbidity, and the difference between the two was used as the amount of blue formazan produced. In addition, it shows that an estrogen-like effect | action is so high that the production amount of blue formazan is large. As a positive control, 10 -9 mol / L estradiol was used.
The calculation method of the estrogen-like action is as follows.
Estrogen-like action rate (%) = A / B × 100
A: Absorbance at the time of adding the test sample B: Absorbance at the time of not adding the test sample In addition, as each test sample, an aqueous solution of the human lysizuka extract (concentration is described in the following table) was used.
［例９：クリーム］
下記表７に示す組成のクリームを以下の方法により各々調製した。
まず、表７に示す成分（１）〜（６）及び（９）を混合し、加熱して７０℃に維持した。この混合物に成分（１１）の一部を加熱して７０℃に維持したものを加え乳化し、さらに、（１１）の残部で溶解した（７）〜（８）及び（１０）を混合した。その後、冷却してクリームを各々得た。
[Example 9: Cream]
Creams having the compositions shown in Table 7 below were prepared by the following methods.
First, components (1) to (6) and (9) shown in Table 7 were mixed, heated and maintained at 70 ° C. A part of component (11) heated to 70 ° C. was added to this mixture to emulsify, and (7) to (8) and (10) dissolved in the remainder of (11) were mixed. Then, it cooled and each cream was obtained.
（試験方法）
被験クリーム１品につき３５〜５９才の女性１５名をパネルとし、毎日朝と夜の２回、１２週間にわたって洗顔後に被験クリームの適量を顔面に塗布した。塗布によるしわ改善効果を以下の基準によって評価し、各評価基準に該当する人数を表７に示した。
(Test method)
A panel of 15 females aged 35 to 59 years old per test cream, and an appropriate amount of the test cream was applied to the face after washing the face twice a morning and night for 12 weeks. The wrinkle improvement effect by application was evaluated according to the following criteria, and the number of people corresponding to each evaluation criterion is shown in Table 7.
（評価基準）
＜評価＞＜内容＞
有効 肌のしわが目立たなくなった。
やや有効 肌のしわがあまり目立たなくなった。
無効 使用前と変化なし。
(Evaluation criteria)
<Evaluation><Contents>
Effective Wrinkles on the skin are not noticeable.
Slightly effective Skin wrinkles are less noticeable.
Invalid No change before use.
（組成及び結果）
表７に示す結果から、ヒトリシズカ８０ｖｏｌ％含水エチルアルコール抽出物及びヒトリシズカ５０ｖｏｌ％含水エチルアルコール抽出物を配合した、本発明品１及び２のクリームは、これらを皮膚に適用することにより、肌のしわを改善することができ、張りのある美しい肌とすることが明らかとなった。 From the results shown in Table 7, the creams of the products 1 and 2 of the present invention containing 80 vol% hydrated ethyl alcohol extract of human lizards and 50 vol% hydrated ethyl alcohol extract of human lizards were applied to the skin to produce wrinkles on the skin. It has been clarified that it can improve the skin and make the skin beautiful and firm.
以下、化粧料への配合例を示すが、これらの処方に限るものではない。
［例１０：クレンジングクリーム］
（成分） （％）
（１）ステアリン酸 ２．０
（２）ステアリルアルコール ３．０
（３）親油型モノステアリン酸グリセリル ２．０
（４）ミツロウ １．５
（５）ワセリン ６．０
（６）流動パラフィン ４０．０
（７）ジメチルポリシロキサン（１００ＣＳ） ０．５
（８）セスキオレイン酸ソルビタン １．０
（９）防腐剤 適量
（１０）トリエタノールアミン １．０
（１１）プロピレングリコール １０．０
（１２）ポリエチレングリコール２００００ ０．５
（１３）カルボキシビニルポリマー ０．０５
（１４）精製水 残量
（１５）ヒトリシズカ５０ｖｏｌ％含水エチルアルコール抽出物＊１ ０．５
（１６）カミツレ抽出物＊２ ０．５
（１７）ウイキョウ抽出物＊３ ０．５
（１８）香料 適量
＊１：例２で製造した抽出物を含有量１％となるように５０ｖｏｌ％含水１，３−ブチレングリコールに溶解したもの
＊２：丸善製薬社製
＊３：丸善製薬社製
（製法）
Ａ．成分（１）〜（９）を加熱溶解し、７０℃に保つ。
Ｂ．成分（１０）〜（１４）を加熱溶解し、７０℃に保つ。
Ｃ．ＢにＡを加え乳化する。
Ｄ．Ｃを冷却後、成分（１５）〜（１８）を加え混合し、クレンジングクリームを得た。
得られたクレンジングクリームは軽やかな伸び広がりでメイクの汚れ落ちもよく、皮膚の老化を防止し、健康的な肌を維持するクレンジングクリームであった。
Hereinafter, examples of blending into cosmetics will be shown, but not limited to these prescriptions.
[Example 10: Cleansing cream]
(Ingredient) (%)
(1) Stearic acid 2.0
(2) Stearyl alcohol 3.0
(3) Lipophilic glyceryl monostearate 2.0
(4) Beeswax 1.5
(5) Vaseline 6.0
(6) Liquid paraffin 40.0
(7) Dimethylpolysiloxane (100CS) 0.5
(8) Sorbitan sesquioleate 1.0
(9) Preservative appropriate amount (10) Triethanolamine 1.0
(11) Propylene glycol 10.0
(12) Polyethylene glycol 20000 0.5
(13) Carboxyvinyl polymer 0.05
(14) Purified water Residual amount (15) Human vol. 50 vol% hydrous ethyl alcohol extract * 1 0.5
(16) Chamomile extract * 2 0.5
(17) Fennel extract * 3 0.5
(18) Fragrance Appropriate amount * 1: What was obtained by dissolving the extract produced in Example 2 in 50 vol% hydrous 1,3-butylene glycol to a content of 1% * 2: Maruzen Pharmaceutical Co., Ltd. * 3: Maruzen Pharmaceutical Co., Ltd. Made (Manufacturing method)
A. Ingredients (1) to (9) are dissolved by heating and maintained at 70 ° C.
B. Ingredients (10) to (14) are dissolved by heating and maintained at 70 ° C.
C. A is added to B and emulsified.
D. After cooling C, components (15) to (18) were added and mixed to obtain a cleansing cream.
The obtained cleansing cream was a mild cleansing cream that spreads lightly and has good makeup removal, prevents skin aging, and maintains healthy skin.
［例１１：洗顔料］
（成分） （％）
（１）ラウリン酸 ５．０
（２）ミリスチン酸 １８．５
（３）ステアリン酸 ６．０
（４）グリセリン １２．０
（５）ポリエチレングリコール１５００ ５．０
（６）水酸化カリウム ６．５
（７）精製水 残量
（８）ヤシ油脂肪酸ジエタノールアミド ５．０
（９）ヤシ油脂肪酸メチルタウリンナトリウム １．８
（１０）ポリオキシエチレン（７．５Ｅ．Ｏ．）ラウリル
エーテル ２．０
（１１）ジステアリン酸エチレングリコール １．０
（１２）ヒドロキシプロピルメチルセルロース１％水溶液 ５．０
（１３）ヒトリシズカ精製水抽出物＊１ ０．５
（１４）ペパーミント抽出物＊２ ０．５
（１５）ムクロジ抽出物＊３ ０．５
（１６）香料 適量
＊１：例３で製造した抽出物を含有量１％となるように５０ｖｏｌ％含水１，３−ブチレングリコールに溶解したもの
＊２：香栄興業社製
＊３：丸善製薬社製
（製法）
Ａ．成分（１）〜（７）を加熱溶解する。
Ｂ．成分（８）〜（１１）を加熱溶解する。
Ｃ．ＡにＢを加え混合する。
Ｄ．Ｃを冷却後、成分（１２）〜（１６）を加え混合し、洗顔料を得る。
得られたクレンジングクリーム及び洗顔料、はキメ細やかな豊かな泡立ちとさっぱりとした使用感を有しており、皮膚の老化を防止し、健康的な肌を維持する洗顔料であった。
[Example 11: Face wash]
(Ingredient) (%)
(1) Lauric acid 5.0
(2) Myristic acid 18.5
(3) Stearic acid 6.0
(4) Glycerin 12.0
(5) Polyethylene glycol 1500 5.0
(6) Potassium hydroxide 6.5
(7) Purified water remaining amount (8) Palm oil fatty acid diethanolamide 5.0
(9) Palm oil fatty acid methyl taurine sodium 1.8
(10) Polyoxyethylene (7.5E.O.) lauryl ether 2.0
(11) Ethylene glycol distearate 1.0
(12) Hydroxypropyl methylcellulose 1% aqueous solution 5.0
(13) Purified water extract * 1 0.5
(14) Peppermint extract * 2 0.5
(15) Mukuroji extract * 3 0.5
(16) Fragrance Appropriate amount * 1: What was obtained by dissolving the extract produced in Example 3 in 50 vol% hydrous 1,3-butylene glycol so as to have a content of 1% * 2: Koei Kogyo Co., Ltd. * 3: Maruzen Pharmaceutical Co., Ltd. Company (production method)
A. Components (1) to (7) are dissolved by heating.
B. Components (8) to (11) are dissolved by heating.
C. Add B to A and mix.
D. After cooling C, components (12) to (16) are added and mixed to obtain a face wash.
The obtained cleansing cream and facial cleanser had a fine and rich foaming and a refreshing feeling of use, and was a facial cleanser that prevented skin aging and maintained healthy skin.
［例１２：化粧水１］
（成分） （％）
（１）クエン酸 ０．０５
（２）クエン酸ナトリウム ０．２
（３）ピロリドンカルボン酸ナトリウム（５０％）液＊１ ０．５
（４）グリセリン ３．０
（５）１，３−ブチレングリコール ８．０
（６）Ｌ−アスコルビン酸２−グルコシド＊２ ２．０
（７）水酸化ナトリウム ０．２５
（８）ヒトリシズカ５０ｖｏｌ％含水エチルアルコール抽出物＊３ １．０
（９）エゾウコギ抽出物＊４ １．０
（１０）ニンジン抽出物＊５ １．０
（１１）精製水 残量
（１２）エチルアルコール １０．０
（１３）香料 適量
（１４）防腐剤 適量
（１５）モノオレイン酸ポリオキシエチレン（２０Ｅ．Ｏ．）
ソルビタン ０．５
＊１：味の素社製
＊２：林原生物化学研究所社製
＊３：例２で製造した抽出物を含有量１％となるように５０ｖｏｌ％含水１，３−ブチレングリコールに溶解したもの
＊４：丸善製薬社製
＊５：丸善製薬社製
（製法）
Ａ．成分（１）〜（１１）を混合溶解する。
Ｂ．成分（１２）〜（１５）を混合溶解する。
Ｃ．ＡにＢを加え混合し、化粧水を得た。
得られた化粧水１はみずみずしくさっぱりとした使用感を有しており、皮膚の老化を防止し、皮膚をみずみずしく保ち、皮膚を滑らかにする化粧水であった。
[Example 12: Lotion 1]
(Ingredient) (%)
(1) Citric acid 0.05
(2) Sodium citrate 0.2
(3) Sodium pyrrolidonecarboxylate (50%) solution * 1 0.5
(4) Glycerin 3.0
(5) 1,3-butylene glycol 8.0
(6) L-ascorbic acid 2-glucoside * 2 2.0
(7) Sodium hydroxide 0.25
(8) Hitorishizuka 50 vol% hydrous ethyl alcohol extract * 3 1.0
(9) Yokogi extract * 4 1.0
(10) Carrot extract * 5 1.0
(11) Purified water remaining amount (12) Ethyl alcohol 10.0
(13) Perfume Appropriate amount (14) Preservative Appropriate amount (15) Polyoxyethylene monooleate (20E.O.)
Sorbitan 0.5
* 1: Ajinomoto Co., Inc. * 2: Hayashibara Biochemical Laboratories Co., Ltd. * 3: The extract produced in Example 2 dissolved in 50 vol% hydrous 1,3-butylene glycol so as to have a content of 1% * 4 : Made by Maruzen Pharmaceutical * 5: Made by Maruzen Pharmaceutical (Manufacturing method)
A. Components (1) to (11) are mixed and dissolved.
B. Components (12) to (15) are mixed and dissolved.
C. B was added to A and mixed to obtain a skin lotion.
The obtained lotion 1 had a fresh and refreshing feeling of use, was a lotion that prevented skin aging, kept the skin fresh and smoothed the skin.
［例１３：化粧水２］
（成分） （％）
（１）メドウホーム油 ０．１
（２）ホホバ油 ０．０５
（３）香料 適量
（４）防腐剤 適量
（５）モノオレイン酸ポリオキシエチレン（２０Ｅ．Ｏ．）
ソルビタン ０．５
（６）イソステアリン酸ポリオキシエチレン硬化
ヒマシ油（５０Ｅ．Ｏ．） １．０
（７）エチルアルコール ８．０
（８）グリセリン ５．０
（９）１，３−ブチレングリコール ５．０
（１０）ポリエチレングリコール１５００ ０．１
（１１）ヒトリシズカ精製水抽出物＊１ １．０
（１２）グリチルリチン酸ジカリウム＊２ ０．５
（１３）レイシ抽出物＊３ ０．５
（１４）精製水 残量
＊１：例３で製造した抽出物を含有量１％となるように５０ｖｏｌ％含水１，３−ブチレングリコールに溶解したもの
＊２：丸善製薬社製
＊３：丸善製薬社製
（製法）
Ａ．成分（１）〜（７）を混合溶解する。
Ｂ．成分（８）〜（１４）を混合溶解する。
Ｃ．ＢにＡを加え混合し、化粧水を得る。
得られた化粧水２はみずみずしくまろやかな使用感を有しており、皮膚の老化を防止し、皮膚をみずみずしく保ち、皮膚を滑らかにする化粧水であった。
[Example 13: Lotion 2]
(Ingredient) (%)
(1) Meadow home oil 0.1
(2) Jojoba oil 0.05
(3) Perfume appropriate amount (4) preservative appropriate amount (5) polyoxyethylene monooleate (20E.O.)
Sorbitan 0.5
(6) Isostearic acid polyoxyethylene hydrogenated castor oil (50 EO) 1.0
(7) Ethyl alcohol 8.0
(8) Glycerin 5.0
(9) 1,3-butylene glycol 5.0
(10) Polyethylene glycol 1500 0.1
(11) Human lizards purified water extract * 1 1.0
(12) Dipotassium glycyrrhizinate * 2 0.5
(13) Ganoderma extract * 3 0.5
(14) Purified water remaining amount * 1: The extract produced in Example 3 was dissolved in 50 vol% water-containing 1,3-butylene glycol so as to have a content of 1%. * 2: Maruzen Pharmaceutical Co., Ltd. * 3: Maruzen Made by Pharmaceutical Co., Ltd.
A. Components (1) to (7) are mixed and dissolved.
B. Components (8) to (14) are mixed and dissolved.
C. A is added to B and mixed to obtain a skin lotion.
The obtained lotion 2 had a fresh and mellow feeling of use, and was a lotion that prevented skin aging, kept the skin fresh and smoothed the skin.
［例１４：化粧水３］
（成分） （％）
（１）トリ２−エチルヘキサン酸グリセリル ０．０８
（２）スクワラン ０．０２
（３）セスキオレイン酸ソルビタン ０．０５
（４）モノオレイン酸ポリオキシエチレン（２０Ｅ．Ｏ．）
ソルビタン ０．０５
（５）ポリオキシエチレン（８Ｅ．Ｏ．）アルキレン（１２〜1５）
エーテルリン酸 ０．１
（６）防腐剤 適量
（７）香料 適量
（８）エチルアルコール ８．０
（９）ジプロプレングリコール ８．０
（１０）グリセリン ４．０
（１１）ヒトリシズカ８０ｖｏｌ％含水エチルアルコール抽出物＊１ ０．５
（１２）ヒアルロン酸ナトリウム１％水溶液＊２ ３．０
（１３）テンチャ抽出物＊３ ０．５
（１４）精製水 残量
＊１：例１で製造した抽出物を含有量１％となるように５０ｖｏｌ％含水１，３−ブチレングリコールに溶解したもの
＊２：紀文フードケミファ社製
＊３：丸善製薬社製
（製法）
Ａ．成分（１）〜（８）を混合溶解する。
Ｂ．成分（９）〜（１４）を混合溶解する。
Ｃ．ＢにＡを加え乳化し、化粧水を得る。
得られた化粧水３はすっきりとした軽やかな使用感を有しており、皮膚の老化を防止し、皮膚をみずみずしく保ち、皮膚を滑らかにする化粧水であった。
[Example 14: Lotion 3]
(Ingredient) (%)
(1) Glyceryl tri-2-ethylhexanoate 0.08
(2) Squalane 0.02
(3) Sorbitan sesquioleate 0.05
(4) Polyoxyethylene monooleate (20E.O.)
Sorbitan 0.05
(5) Polyoxyethylene (8E.O.) alkylene (12 to 15)
Ether phosphoric acid 0.1
(6) Preservative appropriate amount (7) perfume appropriate amount (8) ethyl alcohol 8.0
(9) Dipropylene glycol 8.0
(10) Glycerin 4.0
(11) Hitori Shizuka 80vol% hydrous ethyl alcohol extract * 1 0.5
(12) Sodium hyaluronate 1% aqueous solution * 2 3.0
(13) Tencha extract * 3 0.5
(14) Purified water remaining amount * 1: The extract produced in Example 1 was dissolved in 50 vol% hydrous 1,3-butylene glycol so as to have a content of 1% * 2: manufactured by Kibun Food Chemifa * 3: Made by Maruzen Pharmaceutical Co., Ltd.
A. Components (1) to (8) are mixed and dissolved.
B. Components (9) to (14) are mixed and dissolved.
C. A is added to B and emulsified to obtain a skin lotion.
The obtained lotion 3 had a clean and light feeling of use, was a lotion that prevented skin aging, kept the skin fresh and smoothed the skin.
［例１５：乳液］
（成分） （％）
（１）ステアリン酸 １．０
（２）セタノール ０．５
（３）親油型モノステアリン酸グリセリン ０．５
（４）流動パラフィン ２．０
（５）スクワラン ３．０
（６）ホホバ油 ３．０
（７）パルミチン酸セチル ０．２
（８）防腐剤 適量
（９）モノステアリン酸ソルビタン ０．３
（１０）モノオレイン酸ポリオキシエチレン（２０Ｅ．Ｏ．）
ソルビタン ０．５
（１１）ニコチン酸トコフェロール＊１ ０．１
（１２）トリエタノールアミン ０．５
（１３）１，３−ブチレングリコール １５．０
（１４）グリセリン ３．０
（１５）ポリエチレングリコール６０００ ０．５
（１６）精製水 残量
（１７）カルボキシビニルポリマー１％溶液 ８．０
（１８）ヒトリシズカ５０ｖｏｌ％含水エチルアルコール抽出物＊２ ０．５
（１９）ゲンノショウコ抽出物＊３ ０．５
（２０）シイタケ抽出物＊４ ０．５
（２１）香料 適量
＊１：エーザイ社製
＊２：例２で製造した抽出物を含有量１％となるように５０ｖｏｌ％含水１，３−ブチレングリコールに溶解したもの
＊３：丸善製薬社製
＊４：丸善製薬社製
（製法）
Ａ．成分（１）〜（１１）を加熱溶解し、７０℃に保つ。
Ｂ．成分（１２）〜（１６）を加熱溶解し、７０℃に保つ。
Ｃ．ＡにＢを加え乳化し、更に成分（１７）を加え混合する。
Ｄ．Ｃを冷却し、成分（１８）〜（２１）を加え混合し、乳液を得る。
得られた乳液は滑らかでまろやかな使用感を有しており、皮膚の老化を防止し、皮膚に保湿感と適度なエモリエント感を付与し、皮膚を柔軟にする乳液であった。
[Example 15: Latex]
(Ingredient) (%)
(1) Stearic acid 1.0
(2) Cetanol 0.5
(3) Lipophilic glyceryl monostearate 0.5
(4) Liquid paraffin 2.0
(5) Squalane 3.0
(6) Jojoba oil 3.0
(7) Cetyl palmitate 0.2
(8) Preservative appropriate amount (9) Sorbitan monostearate 0.3
(10) Polyoxyethylene monooleate (20E.O.)
Sorbitan 0.5
(11) Tocopherol nicotinate * 1 0.1
(12) Triethanolamine 0.5
(13) 1,3-butylene glycol 15.0
(14) Glycerin 3.0
(15) Polyethylene glycol 6000 0.5
(16) Purified water remaining amount (17) 1% solution of carboxyvinyl polymer 8.0
(18) Human squirrel 50 vol% hydrous ethyl alcohol extract * 2 0.5
(19) Gennoshoco extract * 3 0.5
(20) Shiitake extract * 4 0.5
(21) Fragrance Appropriate amount * 1: Eisai * 2: The extract produced in Example 2 dissolved in 50 vol% hydrous 1,3-butylene glycol so as to have a content of 1% * 3: Maruzen Pharmaceutical Co., Ltd. * 4: Made by Maruzen Pharmaceutical Co., Ltd.
A. Components (1) to (11) are dissolved by heating and maintained at 70 ° C.
B. Components (12) to (16) are dissolved by heating and maintained at 70 ° C.
C. B is added to A to emulsify, and component (17) is further added and mixed.
D. C is cooled, and components (18) to (21) are added and mixed to obtain an emulsion.
The obtained emulsion had a smooth and mellow feeling of use, prevented the skin from aging, gave the skin a moisturizing feeling and an appropriate emollient feeling, and made the skin soft.
［例１６：クリーム］
（成分） （％）
（１）ステアリン酸 ２．５
（２）セタノール ２．５
（３）親油型モノステアリン酸グリセリン ２．０
（４）ワセリン ２．０
（５）ジペンタエリトリット脂肪酸エステル＊１ ２．０
（６）ミリスチン酸イソトリデシル ５．０
（７）流動パラフィン ８．０
（８）スクワラン ５．０
（９）ミツロウ １．０
（１０）パルミチン酸セチル ２．０
（１１）セスキオレイン酸ソルビタン ０．５
（１２）モノオレイン酸ポリオキシエチレン（２０Ｅ．Ｏ．）
ソルビタン １．５
（１３）防腐剤 適量
（１４）トリエタノールアミン １．２
（１５）１，３−ブチレングリコール ８．０
（１６）グリセリン ２．０
（１７）ポリエチレングリコール２００００ ０．５
（１８）精製水 残量
（１９）カルボキシビニルポリマー１％水溶液 １０．０
（２０）アルブチン＊２ ３．０
（２１）ヒトリシズカ８０ｖｏｌ％含水エチルアルコール抽出物＊３ １．０
（２２）セリン＊４ １．０
（２３）甘草抽出物＊５ ０．５
（２４）ヨクイニン抽出物＊６ ０．５
（２５）香料 適量
＊１：コスモール１６８ＡＲ（日清オイリオグループ社製）
＊２：和光純薬工業社製
＊３：例１で製造した抽出物を含有量１％となるように５０ｖｏｌ％含水１，３−ブチレングリコールに溶解したもの
＊４：味の素社製
＊５：丸善製薬社製
＊６：丸善製薬社製
（製法）
Ａ．成分（１）〜（１３）を加熱溶解し、７０℃に保つ。
Ｂ．成分（１４）〜（１８）を加熱溶解し、７０℃に保つ。
Ｃ．ＡにＢを加え乳化し、更に成分（１９）を加え混合する。
Ｄ．Ｃを冷却し、成分（２０）〜（２５）を加え混合し、クリームを得る。
得られたクリームは滑らかでコクのある使用感を有しており、皮膚の老化を防止し、皮膚に高いエモリエント感を付与し、皮膚を柔軟にするクリームであった。
[Example 16: Cream]
(Ingredient) (%)
(1) Stearic acid 2.5
(2) Cetanol 2.5
(3) Lipophilic glyceryl monostearate 2.0
(4) Vaseline 2.0
(5) Dipentaerythritol fatty acid ester * 1 2.0
(6) Isotridecyl myristate 5.0
(7) Liquid paraffin 8.0
(8) Squalane 5.0
(9) Beeswax 1.0
(10) Cetyl palmitate 2.0
(11) Sorbitan sesquioleate 0.5
(12) Polyoxyethylene monooleate (20E.O.)
Sorbitan 1.5
(13) Preservative appropriate amount (14) Triethanolamine 1.2
(15) 1,3-butylene glycol 8.0
(16) Glycerin 2.0
(17) Polyethylene glycol 20000 0.5
(18) Purified water Remaining amount (19) Carboxyvinyl polymer 1% aqueous solution 10.0
(20) Arbutin * 2 3.0
(21) Human squirrel 80 vol% hydrous ethyl alcohol extract * 3 1.0
(22) Serine * 4 1.0
(23) Licorice extract * 5 0.5
(24) Yokuinin extract * 6 0.5
(25) Perfume appropriate amount * 1: Cosmol 168AR (Nisshin Oillio Group)
* 2: Wako Pure Chemical Industries, Ltd. * 3: The extract produced in Example 1 dissolved in 50 vol% hydrous 1,3-butylene glycol so as to have a content of 1% * 4: Ajinomoto Co. * 5: Made by Maruzen Pharmaceutical Co., Ltd. * 6: Made by Maruzen Pharmaceutical Co., Ltd. (Production method)
A. Ingredients (1) to (13) are dissolved by heating and maintained at 70 ° C.
B. Ingredients (14) to (18) are dissolved by heating and maintained at 70 ° C.
C. B is added to A to emulsify, and component (19) is further added and mixed.
D. C is cooled, components (20) to (25) are added and mixed to obtain a cream.
The obtained cream had a smooth and rich feeling of use, prevented skin aging, imparted a high emollient feeling to the skin, and made the skin soft.
［例１７：美容液］
（成分） （％）
（１）トリ２−エチルヘキサン酸グリセリル ０．１
（２）メドウホーム油 ０．０５
（３）ホホバ油 ０．０５
（４）パルミチン酸レチノール＊１ ０．２
（５）酢酸トコフェロール＊２ ０．１
（６）防腐剤 適量
（７）香料 適量
（８）モノオレイン酸ポリオキシエチレン（２０Ｅ．Ｏ．）
ソルビタン ０．５
（９）イソステアリン酸ポリオキシエチレン硬化
ヒマシ油（５０Ｅ．Ｏ．） １．５
（１０）エチルアルコール ５．０
（１１）グリセリン ４．０
（１２）ジプロピレングリコール ８．０
（１３）１，３−ブチレングリコール ８．０
（１４）乳酸ナトリウム ０．５
（１５）ピロリドンカルボン酸ナトリウム（５０％）液＊３ ０．５
（１６）ヒドロキシエチルセルロース ０．０８
（１７）アルギン酸ナトリウム ０．０５
（１８）ヒトリシズカ８０ｖｏｌ％含水エチルアルコール抽出物＊４ ０．２
（１９）ハマナス抽出物＊５ ０．５
（２０）ゲンチアナ抽出物＊６ ０．５
（２１）精製水 残量
＊１：ロシュ社製
＊２：エーザイ社製
＊３：味の素社製
＊４：例１で製造した抽出物を含有量１％となるように５０ｖｏｌ％含水１，３−ブチレングリコールに溶解したもの
＊５：丸善製薬社製
＊６：丸善製薬社製
（製法）
Ａ．成分（１）〜（９）を混合溶解する。
Ｂ．成分（１０）〜（２１）を混合溶解する。
Ｃ．ＢにＡを加え混合し、美容液を得る。
得られた美容液はまろやかでマイルドな使用感を有しており、皮膚の老化を防止し、皮膚に高い保湿感とエモリエント感を付与し、皮膚をみずみずしく柔軟にする美容液であった。
[Example 17: Cosmetic liquid]
(Ingredient) (%)
(1) Glyceryl tri-2-ethylhexanoate 0.1
(2) Meadow Home Oil 0.05
(3) Jojoba oil 0.05
(4) Retinol palmitate * 1 0.2
(5) Tocopherol acetate * 2 0.1
(6) Preservative appropriate amount (7) perfume appropriate amount (8) polyoxyethylene monooleate (20E.O.)
Sorbitan 0.5
(9) Polyoxyethylene hydrogenated isostearate castor oil (50 EO) 1.5
(10) Ethyl alcohol 5.0
(11) Glycerin 4.0
(12) Dipropylene glycol 8.0
(13) 1,3-butylene glycol 8.0
(14) Sodium lactate 0.5
(15) Sodium pyrrolidonecarboxylate (50%) solution * 3 0.5
(16) Hydroxyethyl cellulose 0.08
(17) Sodium alginate 0.05
(18) Human squirrel 80 vol% hydrous ethyl alcohol extract * 4 0.2
(19) Hermanus extract * 5 0.5
(20) Gentian extract * 6 0.5
(21) Remaining amount of purified water * 1: Roche * 2: Eisai * 3: Ajinomoto * 4: 50 vol% water containing 1,3 so that the extract produced in Example 1 has a content of 1% -Dissolved in butylene glycol * 5: manufactured by Maruzen Pharmaceutical Co., Ltd. * 6: manufactured by Maruzen Pharmaceutical Co., Ltd. (production method)
A. Components (1) to (9) are mixed and dissolved.
B. Components (10) to (21) are mixed and dissolved.
C. A is added to B and mixed to obtain a serum.
The obtained cosmetic liquid had a mellow and mild feeling of use, was a cosmetic liquid that prevented skin aging, imparted a high moisturizing feeling and emollient to the skin, and made the skin fresh and soft.
［例１８：パック（ピールオフ型）］
（成分） （％）
（１）ポリビニルアルコール １２．０
（２）メチルセルロース ０．１
（３）グリセリン ３．０
（４）１，３−ブチレングリコール ５．０
（５）精製水 残量
（６）香料 適量
（７）防腐剤 適量
（８）トリ２−エチルヘキサン酸グリセリル ０．１
（９）モノオレイン酸ポリオキシエチレン（２０Ｅ．Ｏ．）
ソルビタン １．０
（１０）エチルアルコール １３．０
（１１）ヒトリシズカ５０ｖｏｌ％含水エチルアルコール抽出物＊１ ０．５
（１２）甘草抽出物＊２ ０．５
（１３）オノニス抽出物＊３ ０．５
＊１：例２で製造した抽出物を含有量１％となるように５０ｖｏｌ％含水１，３−ブチレングリコールに溶解したもの
＊２：丸善製薬社製
＊３：丸善製薬社製
（製法）
Ａ．成分（１）〜（５）を加熱溶解する。
Ｂ．成分（６）〜（１０）を混合溶解する。
Ｃ．Ａを冷却後、Ｂ、成分（１１）〜（１３）を加え混合し、パックを得る。
得られたパックは適度な清涼感と高い緊張感を有しており、皮膚の老化を防止し、パックした後の皮膚に適度な保湿感とはり感を付与し、皮膚を柔軟にするパックであった。
[Example 18: Pack (Peel-off type)]
(Ingredient) (%)
(1) Polyvinyl alcohol 12.0
(2) Methylcellulose 0.1
(3) Glycerin 3.0
(4) 1,3-butylene glycol 5.0
(5) Purified water remaining amount (6) perfume appropriate amount (7) preservative appropriate amount (8) glyceryl tri-2-ethylhexanoate 0.1
(9) Polyoxyethylene monooleate (20E.O.)
Sorbitan 1.0
(10) Ethyl alcohol 13.0
(11) Hitorishizuka 50 vol% hydrous ethyl alcohol extract * 1 0.5
(12) Licorice extract * 2 0.5
(13) Ononis extract * 3 0.5
* 1: The extract produced in Example 2 dissolved in 50 vol% water-containing 1,3-butylene glycol so as to have a content of 1% * 2: manufactured by Maruzen Pharmaceutical Co., Ltd. * 3: manufactured by Maruzen Pharmaceutical Co., Ltd. (manufacturing method)
A. Components (1) to (5) are dissolved by heating.
B. Components (6) to (10) are mixed and dissolved.
C. After cooling A, B and components (11) to (13) are added and mixed to obtain a pack.
The resulting pack has a moderate refreshing feeling and high tension, prevents skin aging, imparts an appropriate moisturizing feeling and elasticity to the skin after packing, and makes the skin soft. there were.
［例１９：マッサージクリーム］
（成分） （％）
（１）ステアリン酸 ２．０
（２）ステアリルアルコール ２．５
（３）親油型モノステアリン酸グリセリン ２．０
（４）セスキオレイン酸ソルビタン １．０
（５）パルミチン酸セチル １．０
（６）ジペンタエリトリット脂肪酸エステル＊１ ４．０
（７）ワセリン ２０．０
（８）流動パラフィン ２８．０
（９）ジメチルポリシロキサン（１００ＣＳ） ０．５
（１０）水酸化ナトリウム ０．１
（１１）ジプロピレングリコール ７．０
（１２）カルボキシビニルポリマー ０．１
（１３）精製水 残量
（１４）ヒトリシズカ精製水抽出物＊２ ０．５
（１５）加水分解コンキオリン抽出物＊３ ０．５
（１６）ローズマリー抽出物＊４ １．０
（１７）香料 適量
＊１：コスモール１６８ＡＲ（日清オイリオグループ社製）
＊２：例３で製造した抽出物を含有量１％となるように５０ｖｏｌ％含水１，３−ブチレングリコールに溶解したもの
＊３：丸善製薬社製
＊４：丸善製薬社製
（製法）
Ａ．成分（１）〜（９）を加熱溶解し、７０℃に保つ。
Ｂ．成分（１０）〜（１３）を加熱溶解し、７０℃に保つ。
Ｃ．ＢにＡを加え乳化する。
Ｄ．Ｃを冷却後、成分（１４）〜（１７）を加え混合し、マッサージクリームを得た。
得られたマッサージクリームはコクがある滑らかな使用感を有しており、マッサージ効果が高く、皮膚の老化を防止し、皮膚に潤いとはり感を付与し、皮膚を滑らかにするマッサージクリームであった。
[Example 19: Massage cream]
(Ingredient) (%)
(1) Stearic acid 2.0
(2) Stearyl alcohol 2.5
(3) Lipophilic glyceryl monostearate 2.0
(4) Sorbitan sesquioleate 1.0
(5) Cetyl palmitate 1.0
(6) Dipentaerythritol fatty acid ester * 1 4.0
(7) Vaseline 20.0
(8) Liquid paraffin 28.0
(9) Dimethylpolysiloxane (100CS) 0.5
(10) Sodium hydroxide 0.1
(11) Dipropylene glycol 7.0
(12) Carboxyvinyl polymer 0.1
(13) Purified water Residual amount (14) Human squirrel purified water extract * 2 0.5
(15) Hydrolyzed conchiolin extract * 3 0.5
(16) Rosemary extract * 4 1.0
(17) Perfume appropriate amount * 1: Cosmol 168AR (Nisshin Oillio Group)
* 2: The extract produced in Example 3 was dissolved in 50 vol% hydrous 1,3-butylene glycol so as to have a content of 1%. * 3: Made by Maruzen Pharmaceutical Co., Ltd. * 4: Made by Maruzen Pharmaceutical Co., Ltd. (Production method)
A. Ingredients (1) to (9) are dissolved by heating and maintained at 70 ° C.
B. Components (10) to (13) are dissolved by heating and maintained at 70 ° C.
C. A is added to B and emulsified.
D. After cooling C, components (14) to (17) were added and mixed to obtain a massage cream.
The resulting massage cream has a rich and smooth feeling of use, has a high massage effect, prevents skin aging, moisturizes the skin and smoothes the skin. It was.
［例２０：リキッドファンデーション］
（成分） （％）
（１）ステアリン酸 ２．０
（２）セタノール ０．５
（３）ベヘニルアルコール １．０
（４）ワセリン ２．５
（５）流動パラフィン ５．０
（６）自己乳化型モノステアリン酸グリセリン １．０
（７）防腐剤 適量
（８）酸化チタン ６．０
（９）着色顔料 ４．０
（１０）マイカ ２．０
（１１）タルク ４．０
（１２）カルボキシメチルセルロース ０．２
（１３）ベントナイト ０．４
（１４）精製水 残量
（１５）ヒトリシズカ５０ｖｏｌ％含水エチルアルコール抽出物＊１ ０．５
（１６）オウバク抽出物＊２ ０．５
（１７）茶抽出物＊３ ０．５
（１８）香料 適量
＊１：例２で製造した抽出物を含有量１％となるように５０ｖｏｌ％含水１，３−ブチレングリコールに溶解したもの
＊２：丸善製薬社製
＊３：丸善製薬社製
（製法）
Ａ．成分（１）〜（７）を加熱溶解する。
Ｂ．Ａに成分（８）〜（１１）を加え、均一に混合し、７０℃に保つ。
Ｃ．成分（１２）〜（１４）を加熱溶解し、７０℃に保つ。
Ｄ．ＣにＢを加えて乳化する。
Ｅ．Ｄを冷却後、成分（１５）〜（１８）を加え混合し、リキッドファンデーションを得た。
得られたリキッドファンデーションは軽やかな伸び広がりのある使用感を有しており、皮膚の老化を防止し、均一で美しい仕上がりとなるリキッドファンデーションであった。
[Example 20: Liquid foundation]
(Ingredient) (%)
(1) Stearic acid 2.0
(2) Cetanol 0.5
(3) Behenyl alcohol 1.0
(4) Petrolatum 2.5
(5) Liquid paraffin 5.0
(6) Self-emulsifying glyceryl monostearate 1.0
(7) Preservative appropriate amount (8) Titanium oxide 6.0
(9) Color pigment 4.0
(10) Mica 2.0
(11) Talc 4.0
(12) Carboxymethylcellulose 0.2
(13) Bentonite 0.4
(14) Purified water Residual amount (15) Human vol. 50 vol% hydrous ethyl alcohol extract * 1 0.5
(16) Awaku extract * 2 0.5
(17) Tea extract * 3 0.5
(18) Fragrance Appropriate amount * 1: The extract produced in Example 2 dissolved in 50 vol% hydrous 1,3-butylene glycol so as to have a content of 1% * 2: Maruzen Pharmaceutical Co., Ltd. * 3: Maruzen Pharmaceutical Co., Ltd. Made (Manufacturing method)
A. Components (1) to (7) are dissolved by heating.
B. Ingredients (8) to (11) are added to A, mixed uniformly, and kept at 70 ° C.
C. Ingredients (12) to (14) are dissolved by heating and maintained at 70 ° C.
D. B is added to C and emulsified.
E. After cooling D, components (15) to (18) were added and mixed to obtain a liquid foundation.
The obtained liquid foundation was a liquid foundation that had a light and expansive feeling of use, prevented skin aging, and had a uniform and beautiful finish.
本発明の繊維芽細胞賦活剤、ＭＭＰ活性阻害剤、Ｉ型コラーゲン産生促進剤、IV型コラーゲン産生促進剤及びエストロゲン様作用発現剤は、皮膚外用剤、食料品等の有効成分として利用することができる。特に、化粧料等の皮膚外用剤に有用である。 The fibroblast activator, MMP activity inhibitor, type I collagen production promoter, type IV collagen production promoter and estrogen-like action expression agent of the present invention can be used as an active ingredient for external preparations for skin, foods and the like. it can. In particular, it is useful for external preparations for skin such as cosmetics.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006268345A JP5366358B2 (en) | 2006-09-29 | 2006-09-29 | Agent for acting on skin aging mechanism, anti-aging skin external preparation, and anti-aging method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006268345A JP5366358B2 (en) | 2006-09-29 | 2006-09-29 | Agent for acting on skin aging mechanism, anti-aging skin external preparation, and anti-aging method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008088074A JP2008088074A (en) | 2008-04-17 |
| JP5366358B2 true JP5366358B2 (en) | 2013-12-11 |
Family
ID=39372592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006268345A Active JP5366358B2 (en) | 2006-09-29 | 2006-09-29 | Agent for acting on skin aging mechanism, anti-aging skin external preparation, and anti-aging method |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5366358B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009298723A (en) * | 2008-06-12 | 2009-12-24 | Maruzen Pharmaceut Co Ltd | Type iv collagen production promoter |
| AU2010258355B2 (en) * | 2009-06-12 | 2016-04-28 | Generex Pharmaceuticals, Inc. | Compositions and methods for prevention and treatment of coronary heart diseases |
| KR101349248B1 (en) * | 2012-05-24 | 2014-01-13 | (주)아모레퍼시픽 | Compositions containing a dehydro-abietic acid for anti-aging |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3232137B2 (en) * | 1992-08-21 | 2001-11-26 | 丸善製薬株式会社 | Active oxygen scavenger |
| JPH06336417A (en) * | 1993-03-31 | 1994-12-06 | Shiseido Co Ltd | Ultraviolet light absorber and external preparation for skin mixed with the same |
| JP3597210B2 (en) * | 1993-08-27 | 2004-12-02 | 花王株式会社 | Hair restoration |
| JPH07238275A (en) * | 1994-02-28 | 1995-09-12 | Shiseido Co Ltd | Ultraviolet light absorber and skin external preparation containing the same blended therein |
| JP3696862B2 (en) * | 2003-04-23 | 2005-09-21 | 三興物産株式会社 | Method of using moisturizer and plant extract, and external preparation |
| JP4579564B2 (en) * | 2004-03-16 | 2010-11-10 | 花王株式会社 | Wrinkle improving agent |
| JP4425163B2 (en) * | 2005-03-02 | 2010-03-03 | 株式会社ディーエイチシー | Anti-aging cosmetics |
| JP2008088075A (en) * | 2006-09-29 | 2008-04-17 | Kose Corp | Profilaggrin/filaggrin production promoter, epidermal keratinocyte proliferation promoter, skin care preparation for normalizing epidermis/horny cell layer, profilaggrin/filaggrin production-promoting method and epidermal keratinocyte proliferation-promoting method |
| JP5144048B2 (en) * | 2006-09-29 | 2013-02-13 | 株式会社コーセー | Radical scavenger, antioxidant skin external preparation, and radical scavenging method |
-
2006
- 2006-09-29 JP JP2006268345A patent/JP5366358B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008088074A (en) | 2008-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111201012A (en) | Cosmetic composition for skin whitening and wrinkle improvement containing Centella asiatica adventitious root extract as an active ingredient | |
| JP4299374B2 (en) | Cell activator and its application | |
| JP4091825B2 (en) | Skin preparation | |
| KR20050084971A (en) | Composition for preparation for external use on skin and method of using the same | |
| JP4091824B2 (en) | Skin preparation | |
| JP2003300858A (en) | Skin care preparation | |
| KR20150078868A (en) | Cosmetic composition containing ginsenoside Rd, Rb2 and Bambusae Caulis in Taeniam extracts | |
| JP5138262B2 (en) | Topical skin preparation | |
| JP2005247826A (en) | Decorin production-promoting agent and skin care preparation for external use containing the same | |
| JP3278138B2 (en) | External preparation for skin | |
| JP5366358B2 (en) | Agent for acting on skin aging mechanism, anti-aging skin external preparation, and anti-aging method | |
| KR101430636B1 (en) | Functional cosmetic composition comprising ginsenosides Rh2 and Rg3 | |
| JP2015093848A (en) | Skin cosmetic and hair cosmetic | |
| JP2008088075A (en) | Profilaggrin/filaggrin production promoter, epidermal keratinocyte proliferation promoter, skin care preparation for normalizing epidermis/horny cell layer, profilaggrin/filaggrin production-promoting method and epidermal keratinocyte proliferation-promoting method | |
| KR20210060801A (en) | Cosmetic Compositions for Anti-aging Comprising Complex Fermented Product of Plants | |
| CN101106971B (en) | Cosmetic compositions containing sophora alopecuroides extracts | |
| JP2005023021A (en) | Elastase inhibitor | |
| JP5116328B2 (en) | External preparation for skin and food and drink | |
| CN104717957B (en) | Include skin condition improvement composition veratric acid or its salt as active ingredient | |
| JP2006176440A (en) | Bleaching or aging-preventing agent composition for skin and cosmetic | |
| JP5155543B2 (en) | Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method | |
| JP5000964B2 (en) | Testosterone 5α-reductase activity inhibitor, androgen receptor antagonist, use thereof, and method for suppressing androgen activity expression | |
| JP5313524B2 (en) | Anti-inflammatory agent and anti-inflammatory skin external preparation | |
| JP5226200B2 (en) | Sulfated glycosaminoglycan production promoter and skin external preparation containing the same | |
| JP2006241005A (en) | Skin aging-preventing agent and cosmetic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090917 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110721 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110816 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111017 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20120501 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120629 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130422 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130514 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130611 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130716 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130813 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130910 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5366358 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |